JP2015509540A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015509540A5 JP2015509540A5 JP2014561069A JP2014561069A JP2015509540A5 JP 2015509540 A5 JP2015509540 A5 JP 2015509540A5 JP 2014561069 A JP2014561069 A JP 2014561069A JP 2014561069 A JP2014561069 A JP 2014561069A JP 2015509540 A5 JP2015509540 A5 JP 2015509540A5
- Authority
- JP
- Japan
- Prior art keywords
- alk
- disorder
- compound
- salt
- fak
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261607305P | 2012-03-06 | 2012-03-06 | |
| US61/607,305 | 2012-03-06 | ||
| PCT/US2013/029304 WO2013134353A1 (en) | 2012-03-06 | 2013-03-06 | Fused bicyclic 2,4-diaminopyrimidine derivative as a dual alk and fak inhibitor |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016188585A Division JP2017039741A (ja) | 2012-03-06 | 2016-09-27 | 二重のａｌｋおよびｆａｋ阻害剤としての縮合二環式２，４−ジアミノピリミジン誘導体 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015509540A JP2015509540A (ja) | 2015-03-30 |
| JP2015509540A5 true JP2015509540A5 (enExample) | 2016-02-25 |
| JP6016953B2 JP6016953B2 (ja) | 2016-10-26 |
Family
ID=47892060
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014561069A Expired - Fee Related JP6016953B2 (ja) | 2012-03-06 | 2013-03-06 | 二重のａｌｋおよびｆａｋ阻害剤としての縮合二環式２，４−ジアミノピリミジン誘導体 |
| JP2016188585A Pending JP2017039741A (ja) | 2012-03-06 | 2016-09-27 | 二重のａｌｋおよびｆａｋ阻害剤としての縮合二環式２，４−ジアミノピリミジン誘導体 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016188585A Pending JP2017039741A (ja) | 2012-03-06 | 2016-09-27 | 二重のａｌｋおよびｆａｋ阻害剤としての縮合二環式２，４−ジアミノピリミジン誘導体 |
Country Status (28)
| Country | Link |
|---|---|
| US (5) | US9132128B2 (enExample) |
| EP (2) | EP3056494B1 (enExample) |
| JP (2) | JP6016953B2 (enExample) |
| KR (1) | KR102068374B1 (enExample) |
| CN (2) | CN104159894B (enExample) |
| AU (1) | AU2013229995B2 (enExample) |
| CA (1) | CA2865420C (enExample) |
| CL (1) | CL2014002353A1 (enExample) |
| CY (1) | CY1117565T1 (enExample) |
| DK (1) | DK2822939T3 (enExample) |
| EA (2) | EA025859B1 (enExample) |
| ES (2) | ES2681487T3 (enExample) |
| HR (1) | HRP20160387T1 (enExample) |
| HU (1) | HUE027976T2 (enExample) |
| IL (2) | IL234239A (enExample) |
| ME (1) | ME02460B (enExample) |
| MX (2) | MX372740B (enExample) |
| MY (1) | MY177290A (enExample) |
| NZ (1) | NZ630251A (enExample) |
| PH (1) | PH12014501979A1 (enExample) |
| PL (1) | PL2822939T3 (enExample) |
| RS (1) | RS54689B1 (enExample) |
| SG (2) | SG10201507865QA (enExample) |
| SI (1) | SI2822939T1 (enExample) |
| SM (1) | SMT201600134B (enExample) |
| UA (1) | UA115052C2 (enExample) |
| WO (1) | WO2013134353A1 (enExample) |
| ZA (1) | ZA201406147B (enExample) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL2822939T3 (pl) * | 2012-03-06 | 2016-08-31 | Cephalon Inc | Skondensowane bicykliczne pochodne 2,4-diaminopirymidyny jako podwójne inhibitory ALK i FAK |
| CA2946538A1 (en) | 2014-04-04 | 2015-10-08 | Del Mar Pharmaceuticals | Use of dianhydrogalactitol and analogs or derivatives thereof to treat non-small-cell carcinoma of the lung and ovarian cancer |
| HK1244789B (en) * | 2014-12-23 | 2019-12-06 | Cephalon, Inc. | Methods for preparing fused bicyclic 2, 4-diaminopyrimidine derivatives |
| BR112021002145A2 (pt) | 2018-08-07 | 2021-12-14 | In3Bio Ltd | Métodos e composições para inibição da via egf/egfr em combinação com inibidores da quinase de linfoma anaplásico |
| WO2024178339A2 (en) * | 2023-02-23 | 2024-08-29 | The Regents Of The University Of Michigan | Methods for treating neuroblastoma with a dual anaplastic lymphoma kinase and focal adhesion kinase inhibitor |
| WO2024229406A1 (en) | 2023-05-04 | 2024-11-07 | Revolution Medicines, Inc. | Combination therapy for a ras related disease or disorder |
| US20250049810A1 (en) | 2023-08-07 | 2025-02-13 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| TW202530228A (zh) | 2023-10-12 | 2025-08-01 | 美商銳新醫藥公司 | Ｒａｓ抑制劑 |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| TW202547461A (zh) | 2024-05-17 | 2025-12-16 | 美商銳新醫藥公司 | Ｒａｓ抑制劑 |
| WO2025255438A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2025265060A1 (en) | 2024-06-21 | 2025-12-26 | Revolution Medicines, Inc. | Therapeutic compositions and methods for managing treatment-related effects |
| WO2026006747A1 (en) | 2024-06-28 | 2026-01-02 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026015801A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015825A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Use of ras inhibitor for treating pancreatic cancer |
| WO2026015790A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015796A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026050446A1 (en) | 2024-08-29 | 2026-03-05 | Revolution Medicines, Inc. | Ras inhibitors |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2532800C (en) | 2003-07-23 | 2013-06-18 | Exelixis, Inc. | Anaplastic lymphoma kinase modulators and methods of use |
| BR122019017579B8 (pt) | 2003-08-15 | 2021-07-27 | Novartis Ag | 2,4-pirimidinadiaminas, seus usos, combinação e composição farmacêutica |
| CN1918158B (zh) * | 2004-02-14 | 2011-03-02 | Irm责任有限公司 | 作为蛋白激酶抑制剂的化合物和组合物 |
| CA2559866A1 (en) | 2004-03-31 | 2005-10-20 | Exelixis, Inc. | Anaplastic lymphoma kinase modulators and methods of use |
| ES2622493T3 (es) * | 2006-02-24 | 2017-07-06 | Rigel Pharmaceuticals, Inc. | Composiciones y métodos para la inhibición de la ruta de JAK |
| EP2222647B1 (en) | 2006-10-23 | 2015-08-05 | Cephalon, Inc. | Fused bicyclic derivatives of 2,4-diaminopyrimidine as alk and c-met inhibitors |
| KR101364277B1 (ko) * | 2006-12-08 | 2014-02-21 | 아이알엠 엘엘씨 | 단백질 키나제 억제제로서의 화합물 |
| DK2146779T3 (en) * | 2007-04-18 | 2016-11-28 | Pfizer Prod Inc | Sulfonylamid derivatives to treat abnormal cell growth. |
| PL2975024T3 (pl) * | 2009-06-10 | 2018-09-28 | Chugai Seiyaku Kabushiki Kaisha | Związki tetracykliczne |
| PL2822939T3 (pl) * | 2012-03-06 | 2016-08-31 | Cephalon Inc | Skondensowane bicykliczne pochodne 2,4-diaminopirymidyny jako podwójne inhibitory ALK i FAK |
| KR101446742B1 (ko) * | 2012-08-10 | 2014-10-01 | 한국화학연구원 | Ｎ2,ｎ4-비스(4-(피페라진-1-일)페닐)피리미딘-2,4-디아민 유도체 또는 이의 약학적으로 허용가능한 염 및 이를 유효성분으로 함유하는 암의 예방 또는 치료용 약학적 조성물 |
| HK1244789B (en) * | 2014-12-23 | 2019-12-06 | Cephalon, Inc. | Methods for preparing fused bicyclic 2, 4-diaminopyrimidine derivatives |
-
2013
- 2013-03-06 PL PL13710258T patent/PL2822939T3/pl unknown
- 2013-03-06 DK DK13710258.8T patent/DK2822939T3/en active
- 2013-03-06 NZ NZ630251A patent/NZ630251A/en unknown
- 2013-03-06 ES ES15202516.9T patent/ES2681487T3/es active Active
- 2013-03-06 MX MX2017006206A patent/MX372740B/es unknown
- 2013-03-06 RS RS20160238A patent/RS54689B1/sr unknown
- 2013-03-06 EA EA201491641A patent/EA025859B1/ru not_active IP Right Cessation
- 2013-03-06 SG SG10201507865QA patent/SG10201507865QA/en unknown
- 2013-03-06 SI SI201330151T patent/SI2822939T1/sl unknown
- 2013-03-06 ME MEP-2016-68A patent/ME02460B/me unknown
- 2013-03-06 ES ES13710258T patent/ES2570976T3/es active Active
- 2013-03-06 CN CN201380012764.6A patent/CN104159894B/zh active Active
- 2013-03-06 CN CN201610591742.5A patent/CN106166155B/zh active Active
- 2013-03-06 EP EP15202516.9A patent/EP3056494B1/en active Active
- 2013-03-06 HU HUE13710258A patent/HUE027976T2/en unknown
- 2013-03-06 JP JP2014561069A patent/JP6016953B2/ja not_active Expired - Fee Related
- 2013-03-06 UA UAA201410832A patent/UA115052C2/uk unknown
- 2013-03-06 KR KR1020147027590A patent/KR102068374B1/ko active Active
- 2013-03-06 SG SG11201405371PA patent/SG11201405371PA/en unknown
- 2013-03-06 HR HRP20160387TT patent/HRP20160387T1/hr unknown
- 2013-03-06 CA CA2865420A patent/CA2865420C/en active Active
- 2013-03-06 MY MYPI2014002428A patent/MY177290A/en unknown
- 2013-03-06 EP EP13710258.8A patent/EP2822939B1/en active Active
- 2013-03-06 WO PCT/US2013/029304 patent/WO2013134353A1/en not_active Ceased
- 2013-03-06 MX MX2014010613A patent/MX347772B/es active IP Right Grant
- 2013-03-06 AU AU2013229995A patent/AU2013229995B2/en active Active
- 2013-03-06 EA EA201691574A patent/EA033124B1/ru not_active IP Right Cessation
-
2014
- 2014-08-21 ZA ZA2014/06147A patent/ZA201406147B/en unknown
- 2014-08-21 IL IL234239A patent/IL234239A/en active IP Right Grant
- 2014-09-02 US US14/474,928 patent/US9132128B2/en active Active
- 2014-09-05 PH PH12014501979A patent/PH12014501979A1/en unknown
- 2014-09-05 CL CL2014002353A patent/CL2014002353A1/es unknown
-
2015
- 2015-08-12 US US14/824,750 patent/US9339502B2/en active Active
-
2016
- 2016-05-04 US US15/146,164 patent/US9623026B2/en not_active Expired - Fee Related
- 2016-05-10 SM SM201600134T patent/SMT201600134B/it unknown
- 2016-05-10 CY CY20161100390T patent/CY1117565T1/el unknown
- 2016-09-27 JP JP2016188585A patent/JP2017039741A/ja active Pending
-
2017
- 2017-03-07 US US15/451,960 patent/US10111872B2/en active Active
- 2017-05-18 IL IL252364A patent/IL252364B/en active IP Right Grant
-
2018
- 2018-10-26 US US16/172,368 patent/US10632119B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015509540A5 (enExample) | ||
| JP2015536964A5 (enExample) | ||
| EA201690322A1 (ru) | Терапевтически активные соединения и способы их применения | |
| HRP20160387T1 (hr) | Spojeni biciklični 2,4-diaminopirimidin derivat kao dualni alk i fak inhibitor | |
| JP2016501221A5 (enExample) | ||
| JP2013064024A5 (enExample) | ||
| JP2016533366A5 (enExample) | ||
| PH12015501517A1 (en) | Pyrimidone derivatives and their use in the treatment, amelioration or prevention of a viral disease | |
| PH12015502628B1 (en) | Pyrazolopyrrolidine derivatives and their use in the treatment of disease | |
| JP2015512398A5 (enExample) | ||
| EA201590345A1 (ru) | Способы лечения рака с использованием 3-(4-((4-(морфолинометил)бензил)окси)-1-оксоизоиндолин-2-ил)пиперидин-2,6-диона | |
| JP2017537066A5 (enExample) | ||
| MX2015016344A (es) | Derivados de imidazo-pirrolidinona y su uso en el tratamiento de enfermedades. | |
| JP2014527042A5 (enExample) | ||
| IN2014CN00408A (enExample) | ||
| JP2016518337A5 (enExample) | ||
| JP2013507415A5 (enExample) | ||
| JP2015193630A5 (enExample) | ||
| EA201690741A1 (ru) | Составы (s)-3-(4-((4-(морфолинометил)бензил)окси)-1-оксоизоиндолин-2-ил)пиперидин-2,6-диона | |
| HRP20230477T1 (hr) | Spojevi i pripravci uree kao inhibitori smarca2/brm-atpaze | |
| MX2015016425A (es) | Derivados de pirazolo-pirrolidin-4-ona y su uso en el tratamiento de enfermedades. | |
| JP2014509653A5 (enExample) | ||
| JP2015502926A5 (enExample) | ||
| MX2016002795A (es) | Compuestos de triazolona y usos de los mismos. | |
| BR112015016184A2 (pt) | derivados de piridona e seu uso no tratamento, melhora ou prevenção de uma doença viral |